Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)Defense World · Oct 5, 2026
These beaten-down stocks could bounce back in January, if history is any guideMarket Watch · Sep 21, 2026
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026GlobeNewsWire · Sep 8, 2026
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNPGlobeNewsWire · Sep 1, 2026
Fannie Mae Announces Sale of Non-Performing LoansGuruFocus · Aug 19, 2026
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research · Aug 11, 2026Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.78 | -$0.73 | Beat |
| May 13, 2026 | -$0.75 | -$0.75 | Beat |
| Mar 26, 2026 | -$0.73 | -$0.79 | Miss |
| Nov 5, 2025 | -$0.78 | -$0.63 | Beat |
| Aug 6, 2025 | -$0.61 | -$0.74 | Miss |
| May 6, 2025 | -$0.49 | -$0.51 | Miss |